TNYAClinical Trials•globenewswire•
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
Sentiment:Negative (35)
Summary
(NASDAQ:TNYA) Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 31, 2025 by globenewswire